These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8787101)

  • 21. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.
    de Boer SF; Koolhaas JM
    Eur J Pharmacol; 2005 Dec; 526(1-3):125-39. PubMed ID: 16310183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buspirone and serotonin in spinocerebellar ataxia.
    Gazulla J; Modrego P
    J Neurol Sci; 2008 May; 268(1-2):199-200; author reply 200-1. PubMed ID: 18222483
    [No Abstract]   [Full Text] [Related]  

  • 23. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing.
    Trouillas P; Brudon F; Adeleine P
    Arch Neurol; 1988 Nov; 45(11):1217-22. PubMed ID: 3190503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
    Haleem DJ; Samad N; Haleem MA
    Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of diminished and conflicting sensory information on balance in patients with cerebellar deficits.
    Gatev P; Thomas S; Lou JS; Lim M; Hallett M
    Mov Disord; 1996 Nov; 11(6):654-64. PubMed ID: 8914091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological treatments of cerebellar ataxia.
    Ogawa M
    Cerebellum; 2004; 3(2):107-11. PubMed ID: 15233578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: a quantitative ELISA study.
    Buritova J; Berrichon G; Cathala C; Colpaert F; Cussac D
    Neuropharmacology; 2009 Feb; 56(2):350-61. PubMed ID: 18809418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Steroid treatment in four cases of anti-GAD cerebellar ataxia].
    Bonnan M; Cabre P; Olindo S; Signate A; Saint-Vil M; Smadja D
    Rev Neurol (Paris); 2008 May; 164(5):427-33. PubMed ID: 18555874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of spinocerebellar ataxia with buspirone.
    Assadi M; Campellone JV; Janson CG; Veloski JJ; Schwartzman RJ; Leone P
    J Neurol Sci; 2007 Sep; 260(1-2):143-6. PubMed ID: 17512011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL; Gupta V; Alam S; Park JY; Bishop C
    Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic buspirone treatment normalizes regional serotonin synthesis in the olfactory bulbectomized rat brain: an autoradiographic study.
    Watanabe A; Hasegawa S; Nishi K; Nguyen KQ; Diksic M
    Brain Res Bull; 2006 Mar; 69(2):101-8. PubMed ID: 16533657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose piracetam is effective on cerebellar ataxia in patient with cerebellar cortical atrophy.
    Vural M; Ozekmekçi S; Apaydin H; Altinel A
    Mov Disord; 2003 Apr; 18(4):457-9. PubMed ID: 12671958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormonal response to buspirone is not impaired in major depression.
    Navinés R; Gómez-Gil E; Martín-Santos R; de Osaba MJ; Escolar G; Gastó C
    Hum Psychopharmacol; 2007 Aug; 22(6):389-95. PubMed ID: 17563921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of buspirone on challenging behaviour in mentally retarded patients: an open prospective multiple-case study.
    Verhoeven WM; Tuinier S
    J Intellect Disabil Res; 1996 Dec; 40 ( Pt 6)():502-8. PubMed ID: 9004110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of a serotonin 1A receptor agonist to treat restless legs syndrome.
    Shioda K; Nisijima K; Yamauchi Y; Ohtuka K; Kato S
    J Clin Psychopharmacol; 2006 Dec; 26(6):673-5. PubMed ID: 17110833
    [No Abstract]   [Full Text] [Related]  

  • 36. An open trial of buspirone in the treatment of attention-deficit disorder.
    Niederhofer H
    Hum Psychopharmacol; 2003 Aug; 18(6):489-92. PubMed ID: 12923830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients.
    Ince Gunal D; Agan K; Afsar N; Borucu D; Us O
    J Clin Pharm Ther; 2008 Apr; 33(2):175-8. PubMed ID: 18315783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment.
    du Montcel ST; Charles P; Ribai P; Goizet C; Le Bayon A; Labauge P; Guyant-Maréchal L; Forlani S; Jauffret C; Vandenberghe N; N'guyen K; Le Ber I; Devos D; Vincitorio CM; Manto MU; Tison F; Hannequin D; Ruberg M; Brice A; Durr A
    Brain; 2008 May; 131(Pt 5):1352-61. PubMed ID: 18378516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postural responses to multidirectional stance perturbations in cerebellar ataxia.
    Bakker M; Allum JH; Visser JE; Grüneberg C; van de Warrenburg BP; Kremer BH; Bloem BR
    Exp Neurol; 2006 Nov; 202(1):21-35. PubMed ID: 16808916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin-like growth factor I treatment for cerebellar ataxia: addressing a common pathway in the pathological cascade?
    Fernandez AM; Carro EM; Lopez-Lopez C; Torres-Aleman I
    Brain Res Brain Res Rev; 2005 Dec; 50(1):134-41. PubMed ID: 15950289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.